EUVIMEDEUVIMED entdecken
Crossref

Serum Galectin-3 in Hepatitis B e-Antigen-Negative Chronic Hepatitis B Virus Infection: Clinical and Histological Correlations

Yıldız Garip Bilen iD, Erdem Akbal

Viral Immunology · 2025

DOI: 10.1177/08828245251374666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viral Immunology, 2025. Verfasst von Yıldız Garip Bilen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B e Antigens, Galectin 3. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims: Chronic hepatitis B (CHB) drives liver fibrosis, contributing to chronic liver disease. Galectin-3 (Gal-3), a lectin linked to inflammation and fibrosis, was investigated for its association with liver injury severity in HBeAg-negative CHB and chronic hepatitis B virus (HBV) infection (CHI) patients.

Methods

We enrolled 25 CHB, 25 CHI, and 25 healthy controls. Serum Gal-3 levels were measured in all subjects, with liver biopsies performed in CHB patients. Gal-3 and HBV DNA levels were monitored at 0, 1, 3, 6, and 12 months during antiviral therapy in CHB patients.

Results

Serum Gal-3 levels were significantly higher in CHI (median: 422 U/L, interquartile range [IQR]: 144–900) and CHB (median: 567 U/L, IQR: 196–1093) patients than controls (median: 179 U/L, IQR: 79–350; p < 0.001). Although Gal-3 levels were higher in CHB than CHI, the difference was not significant ( p = 0.08). Median Gal-3 levels in CHB patients decreased from 567 U/L to 288 U/L after 12 months of antiviral therapy ( p = 0.043 after excluding an outlier). Gal-3 levels showed weak correlations with HBV DNA (Spearman’s rho = 0.32, p = 0.12), ALT (rho = 0.28, p = 0.17), and fibrosis scores (rho = 0.35, p = 0.09).

Conclusions

Elevated Gal-3 levels correlate with HBeAg-negative CHB and CHI, with a significant decline posttreatment in CHB. If validated, Gal-3 could serve as a noninvasive marker for fibrosis and treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B e AntigensGalectin 3HumansMaleFemaleAdultMiddle AgedDNA, ViralLiverLiver CirrhosisAntiviral AgentsBiomarkersHepatitis B virusBiopsyBlood ProteinsGalectins

Stichwörter der Autor:innen

Galectin-3HBVbiomarkerchronic hepatitis Bliver fibrosisliver histology

Substanzen

Hepatitis B e AntigensGalectin 3DNA, ViralAntiviral AgentsBiomarkersLGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • Department of Medical Oncology, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey.
  • Department of Gastroenterology, Memorial Şişli Hospital, İstanbul, Turkey.

ORCID-Profile: Yıldız Garip Bilen

Zitieren

APA

Garip Bilen, Y., & Akbal, E. (2025). Serum Galectin-3 in Hepatitis B e-Antigen-Negative Chronic Hepatitis B Virus Infection: Clinical and Histological Correlations. Viral Immunology. https://doi.org/10.1177/08828245251374666

Vancouver

Garip Bilen Y, Akbal E. Serum Galectin-3 in Hepatitis B e-Antigen-Negative Chronic Hepatitis B Virus Infection: Clinical and Histological Correlations. Viral Immunology. 2025. doi:10.1177/08828245251374666

BibTeX
@article{GaripBilen2025,
  author = {Garip Bilen, Yıldız and Akbal, Erdem},
  title = {Serum Galectin-3 in Hepatitis B e-Antigen-Negative Chronic Hepatitis B Virus Infection: Clinical and Histological Correlations},
  journal = {Viral Immunology},
  year = {2025},
  doi = {10.1177/08828245251374666}
}
Kostenlos starten →